Vertex Pharmaceuticals Incorporated Announces Revenue Results for the Fourth Quarter and Full Year of 2015; Provides Revenuer Guidance for the Year 2016
For the year, the company net product Revenue was $350 million for orkambi and $630 million for kalydeco.
The company provided revenuer guidance for the year 2016. For the year, the company provided guidance for KALYDECO net product revenues of $670 million to $690 million and for non-GAAP operating expenses, excluding costs of revenues, of $1.18 to $1.23 billion.